Dr Bob Taylor
Contact information
Research groups
Bob Taylor
Senior Clinical Research Fellow
Vivax malaria
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine is currently the only available drug to prevent relapse infections but can cause severe haemolysis in patients with reduced G6PD activity. Dr Taylor's research aims to determine the most effective and safest way to radically cure vivax malaria.
Podcast interview
Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
Recent publications
-
A preliminary epidemiological study of pinworm infection in Thaklong Municipal Early Childhood Development Center and Rangsit Babies’ Home, Pathum Thani, Thailand
Taylor A. et al, (2018), BMC Research Notes, 11
-
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group
Thriemer K. et al, (2018), Malaria Journal, 17
-
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria – a proposed model-derived age-based regimen for sub-Saharan Africa
Taylor WR. et al, (2018), BMC Medicine, 16
-
Population structures of Leishmania infantum and Leishmania tropica the causative agents of kala-azar in Southwest Iran
Ghatee MA. et al, (2018), Parasitology Research, 117, 3447 - 3458
-
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
Commons RJ. et al, (2018), The Lancet Infectious Diseases, 18, 1025 - 1034